

产品名称: **Trelagliptin (succinate)**
 产品别名: **SYR-472 succinate; 曲格列汀琥珀酸盐**

生物活性:

Description	<p>Trelagliptin succinate (SYR-472 succinate) is a long acting dipeptidyl peptidase-4 (DPP-4) inhibitor that is being developed for the treatment of type 2 diabetes (T2D). IC50 value: Target: DPP4 Two Phase II clinical studies have been completed with Efficacy and Safety of SYR-472 in Subjects With Type 2 Diabetes Mellitus. Phase III clinical studies with trelagliptin in Japan to evaluate its safety and efficacy in a once-weekly oral treatment regimen. Currently, all available DPP-4 inhibitors are dosed once-daily. A once-weekly treatment, such as trelagliptin, would provide patients with a convenient treatment alternative and has the potential to improve treatment compliance.</p>																						
Solvent&Solubility	<p>In Vitro:</p> <p>DMSO : ≥ 50 mg/mL (105.16 mM)</p> <p>* "≥" means soluble, but saturation unknown.</p> <table><tr><th rowspan="2">Preparing Stock Solutions</th><th>Solvent / Mass Concentration</th><th>1 mg</th><th>5 mg</th><th>10 mg</th></tr><tr><th></th><th></th><th></th><th></th></tr><tr><td rowspan="3"></td><td>1 mM</td><td>2.1032 mL</td><td>10.5159 mL</td><td>21.0318 mL</td></tr><tr><td>5 mM</td><td>0.4206 mL</td><td>2.1032 mL</td><td>4.2064 mL</td></tr><tr><td>10 mM</td><td>0.2103 mL</td><td>1.0516 mL</td><td>2.1032 mL</td></tr></table> <p>*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。</p> <p>储备液的保存方式和期限：-80℃, 6 months; -20℃, 1 month。 -80℃ 储存时，请在 6 个月内使用，-20℃ 储存时，请在 1 个月内使用。</p> <p>In Vivo:</p> <p>请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：</p> <p>——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶</p> <p>1.请依序添加每种溶剂： 10% DMSO→40% PEG300 →5% Tween-80 → 45% saline</p> <p>Solubility: ≥ 2.5 mg/mL (5.26 mM); Clear solution</p> <p>此方案可获得 ≥ 2.5 mg/mL (5.26 mM, 饱和度未知) 的澄清溶液。</p> <p>以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入 50 μL Tween-80，混合均匀；然后继续加入 450 μL 生理盐水定容至 1 mL。</p> <p>2.请依序添加每种溶剂： 10% DMSO→ 90% (20% SBE-β-CD in saline)</p> <p>Solubility: ≥ 2.5 mg/mL (5.26 mM); Clear solution</p> <p>此方案可获得 ≥ 2.5 mg/mL (5.26 mM, 饱和度未知) 的澄清溶液。</p> <p>以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。</p> <p>3.请依序添加每种溶剂： 10% DMSO →90% corn oil</p> <p>Solubility: ≥ 2.5 mg/mL (5.26 mM); Clear solution</p> <p>此方案可获得 ≥ 2.5 mg/mL (5.26 mM, 饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的</p>	Preparing Stock Solutions	Solvent / Mass Concentration	1 mg	5 mg	10 mg						1 mM	2.1032 mL	10.5159 mL	21.0318 mL	5 mM	0.4206 mL	2.1032 mL	4.2064 mL	10 mM	0.2103 mL	1.0516 mL	2.1032 mL
Preparing Stock Solutions	Solvent / Mass Concentration		1 mg	5 mg	10 mg																		
	1 mM	2.1032 mL	10.5159 mL	21.0318 mL																			
	5 mM	0.4206 mL	2.1032 mL	4.2064 mL																			
	10 mM	0.2103 mL	1.0516 mL	2.1032 mL																			

	<p>实验。</p> <p>以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 玉米油中，混合均匀。</p>
References	<p>[1]. Efficacy of SYR-472 in Subjects With Type 2 Diabetes Mellitus</p> <p>[2]. Efficacy and Safety of SYR-472 in Subjects With Type 2 Diabetes Mellitus</p> <p>[3]. Long-term Study of SYR-472</p> <p>[4]. SYR-472 Open-label Study</p>



源叶生物